Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: The Austrian Breast and Colorectal Cancer Study Group

Journal of Clinical Oncology

Volumn 23, Issue 6, 2005, Pages 1161-1168

  Filipits, Martin ^a   Pohl, Gudrun ^a   Rudas, Margaretha ^a   Dietze, Otto ^a   Lax, Sigurd ^a   Grill, Renate ^a   Pirker, Robert ^a   Zielinski, Christoph C ^a   Hausmaninger, Hubert ^a   Kubista, Ernst ^a   Samonigg, Hellmut ^a   Jakesz, Raimund ^a  

^a HANUSCH HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; GOSERELIN; HORMONE RECEPTOR; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; TAMOXIFEN; TAMOXIFEN CITRATE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CMF REGIMEN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL; TISSUE SECTION; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; AUSTRIA; BREAST TUMOR; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; FEMALE; METABOLISM; MORTALITY; MULTIDRUG RESISTANCE; NEOPLASM; PREMENOPAUSE;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRIA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, MULTIPLE; FEMALE; FLUOROURACIL; GOSERELIN; HUMANS; METHOTREXATE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PREMENOPAUSE; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 20044364737     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.033     Document Type: Article

References (28)

1. Gottesman MM, Fojo T, Bates SE: Multi-drug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2:48-58, 2002
2. Borst P, Evers R, Kool M, et al: A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302, 2000
3. Trock BJ, Leonessa F, Clarke R: Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 89:917-931, 1997
4. Cole SPC, Bhardwaj G, Gerlach JH, et al: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654, 1992
5. Cole SPC, Sparks KE, Fraser K, et al: Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902-5910, 1994
6. Hooijberg JH, Broxterman HJ, Kool M, et al: Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59:2532-2535, 1999
7. Zeng H, Chen Z-S, Belinsky MG, et al: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: Effect of polyglutamylation on MTX transport. Cancer Res 61:7225-7232, 2001
8. Goldhirsch A, Wood WC, Gelber RD, et al: Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357-3365, 2003
9. Leonessa F, Clarke R: ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10:43-73, 2003
10. Jakesz R, Hausmaninger H, Kubista E, et al: Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20:4621-4627, 2002
11. Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J Clin Oncol 21:3594-3600, 2003
12. Rudas M, Filipits M, Taucher S, et al: Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast Cancer Res Treat 81:149-157, 2003
13. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
14. Cox DR: Regression models and life tables. J R Stat Soc 34:187-220, 1972
15. Bast RC Jr, Ravdin P, Hayes DF, et al: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865-1878, 2001
16. Filipits M, Malayeri R, Suchomel RW, et al: Expression of the multidrug resistance protein (MRP1) in breast cancer. Anticancer Res 19:5043-5050, 1999
17. Nooter K, Brutel de la Riviere G, Klijn J, et al: Multidrug resistance protein in recurrent breast cancer. Lancet 349:1885-1886, 1997
18. Nooter K, Brutel de la Riviere G, Look MP, et al: The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer 76:486-493, 1997
19. Burger H, Foekens JA, Look MP, et al: RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: Correlation with chemotherapeutic response. Clin Cancer Res 9:827-836, 2003
20. Filipits M, Suchomel RW, Dekan G, et al: MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res 2:1231-1237, 1996
21. Dexter DW, Reddy RK, Geles KG, et al: Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma. Clin Cancer Res 4:1533-1542, 1998
22. Ito K, Fujimori M, Nakata S, et al: Clinical significance of the increased multidrug resistance-associated protein (MRP) gene expression in patients with primary breast cancer. Oncol Res 10:99-109, 1998
23. Lacave R, Coulet F, Ricci S, et al: Comparative evaluation by semiquantitative reverse transcriptase polymerase chain reaction of MDR1, MRP and GSTp gene expression in breast carcinomas. Br J Cancer 77:694-702, 1998
24. Ferrero JM, Etienne MC, Formento JL, et al: Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients. Br J Cancer 82:171-177, 2000
25. Kanzaki A, Toi M, Nakayama K, et al: Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res 92:452-458, 2001
26. Linn SC, Pinedo HM, van Ark-Otte J, et al: Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 71:787-795, 1997
27. Zöchbauer-Müller S, Filipits M, Rudas M, et al: P-glycoprotein and MRP1 expression in axillary lymph node metastases of breast cancer patients. Anticancer Res 21:119-124, 2001
28. National Institutes of Health Consensus Development Panel: National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 30:5-15, 2001